Comparison of the contributions of cytochromes P450 3A4 and 3A5 in drug oxidation rates and substrate inhibition

Journal of Health Science

Volumn 56, Issue 3, 2010, Pages 239-256

  Niwa, Toshiro ^a   Murayama, Norie ^a   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cytochrome P450 3A4; Cytochrome P450 3A5; Inhibition constant; Mechanism based inhibition; Meta analysis; Metabolic activity

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIHYDROPYRIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; IMMUNOSUPPRESSIVE AGENT; INSECTICIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE V INHIBITOR; PROKINETIC AGENT; PSYCHOTROPIC AGENT; STEROID HORMONE; VASODILATOR AGENT;

ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE COMPLEX; INHIBITION KINETICS; MICHAELIS CONSTANT; MOLECULAR WEIGHT;

EID: 77953296304     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.56.239     Document Type: Article

References (89)

1. Wilkinson, G. R. (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm., 24, 475-490.
2. Daly, A. K. (2006) Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet., 45, 13-31.
3. Bu, H. Z. (2006) A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Curr. DrugMetab., 7, 231-249.
4. Kuehl, P., Zhang, J., Lin, Y, Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C, Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S. and Schuetz, E. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet, 27, 383-391.
5. de Wildt, S. N., Kearns, G. L., Leeder, J. S. and van den Anker, J. N. (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet, 37,485-505.
6. McConn, D. J., 2nd, Lin, Y. S., Allen, K., Kunze, K. L. and Thummel, K. E. (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. DrugMetab. Dispos., 32, 1083-1091.
7. Niwa, T, Murayama, N., Emoto, C. and Yamazaki, H. (2008) Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. DrugMetab., 9, 20-33.
8. Liu, K. H., Kim, M. G., Lee, D. J., Yoon, Y. J., Kim, M. J., Shon, J. H., Choi, C. S., Choi, Y K., Desta, Z. and Shin, J. G. (2006) Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab. Dispos., 34, 1793-1797.
9. Khojasteh-Bakht, S. C, Rossulek, M. I, Fouda, H. G. and Prakash, C. (2003) Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543. Xenobiotica, 33, 1201-1210.
10. Dai, Y, Iwanaga, K., Lin, Y S., Hebert, M. E, Davis, C. L., Huang, W., Kharasch, E. D. and Thummel, K. E. (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem. Pharmacol., 68, 1889-1902.
11. Fischer, V., Johanson, L., Heitz, F, Tullman, R., Graham, E., Baldeck, J. P. and Robinson, W. T. (1999) The 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos., 27, 410-416.
12. Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L. and Thummel, K. E. (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos., 32, 1121-1131.
13. Huang, W., Lin, Y S., McConn, D. J., 2nd, Calamia, J. C, Totah, R. A., Isoherranen, N., Glodowski, M. and Thummel, K. E. (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab. Dispos., 32, 1434-1445.
14. Henshall, J., Galetin, A., Harrison, A. and Houston, J. B. (2008) Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications. Drug Metab. Dispos., 36, 1332-1340.
15. Nakasa, H., Nakamura, H., Ono, S., Tsutsui, M., Kiuchi, M., Ohmori, S. and Kitada, M. (1998) Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol., 54, 177-183.
16. Grace, J. M., Aguilar, A. J., Trotman, K. M., Peggins, J. O. and Brewer, T. G. (1998) Metabolism of yS arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos., 26, 313-317.
17. Grace, J. M., Skanchy, D. J. and Aguilar, A. J. (1999) Metabolism of artelinic acid to dihydroqinghaosu by human liver cytochrome P4503A. Xenobiotica, 29, 703-717.
18. Allqvist, A., Miura, J., Bertilsson, L. and Mirghani, R. A. (2007) Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol., 63, 173-179.
19. Jones, D. R., Gorski, J. C, Hamman, M. A., Mayhew, B. S., Rider, S. and Hall, S. D. (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther., 290, 1116-1125.
20. Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D. and Wrighton, S. A. (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos., 30, 883-891.
21. Yamaori, S., Yamazaki, H., Iwano, S., Kiyotani, K., Matsumura, K., Saito, T., Parkinson, A., Nakagawa, K. and Kamataki, T. (2005) Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xeno-biotica, 35, 69-83.
22. Shen, L., Fitzloff, J. F. and Cook, C. S. (2004) Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos., 32, 186-196.
23. Li, J., Zhao, M., He, P., Hidalgo, M. and Baker, S. D. (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res., 13, 3731-3737.
24. Zhuo, X., Zheng, N., Felix, C. A. and Blair, I. A. (2004) Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab. Dispos., 32, 993-1000.
25. McCune, J. S., Risler, L. J., Phillips, B. R., Thummel, K. E., Blough, D. and Shen, D. D. (2005) Contribution of CYP3A5 to hepatic and renal ifosfamide Af-dechloroethylation. Drug Metab. Dispos., 33, 1074-1081.
26. Dennison, J. B., Kulanthaivel, P., Barbuch, R. J., Renbarger, J. L., Ehlhardt, W. J. and Hall, S. D. (2006) Selective metabolism of vincristine in vitro by CYP3 A5. Drug Metab. Dispos., 34,1317-1327.
27. Patki, K. C, Von Moltke, L. L. and Greenblatt, D. J. (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos., 31, 938-944.
28. Yoon, Y. J., Kim, K. B., Kim, H., Seo, K. A., Kim, H. S., Cha, I. J., Kim, E. Y, Liu, K. H. and Shin, J. G. (2007) Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab. Dispos., 35, 1518-1524.
29. Walsky, R. L. and Obach, R. S. (2004) Validated assays for human cytochrome P450 activities. Drug Metab. Dispos., 32, 647-660.
30. Park, J. E., Kim, K. B., Bae, S. K., Moon, B. S., Liu, K. H. and Shin, J. G. (2008) Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica, 38, 1240-1251.
31. Picard, N., Djebli, N., Sauvage, F. L. and Marquet, P. (2007) Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab. Dispos., 35, 350-355.
32. Dai, Y, Hebert, M. E, Isoherranen, N., Davis, C. L., Marsh, C, Shen, D. D. and Thummel, K. E. (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos., 34, 836-847.
33. Emoto, C, Nishida, H., Hirai, H. and Iwasaki, K. (2007) CYP3A4 and CYP3A5 catalyse the conversion of the Af-methyl-D aspartate (NMDA) antagonist CJ-036878 to two novel dimers. Xenobiotica, 37, 1408-1420.
34. Klees, T. M., Sheffels, P., Dale, O. and Kharasch, E. D. (2005) Metabolism of alfentanil by cytochrome P4503A (CYP3A) enzymes. Drug Metab. Dispos., 33, 303-311.
35. Ramirez, J., Innocenti, E, Schuetz, E. G., Flockhart, D. A., Relling, M. V, Santucci, R. and Ratain, M. J. (2004) CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab. Dispos., 32, 930-936.
36. Lalovic, B., Phillips, B., Risler, L. L., Howald, W. and Shen, D. D. (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos., 32, 447-454.
37. Ku, H. Y, Ahn, H. J., Seo, K. A., Kim, H., Oh, M., Bae, S. K., Shin, J. G., Shon, J. H. and Liu, K. H. (2008) The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab. Dispos., 36, 986-990.
38. Kim, K. B., Seo, K. A., Yoon, Y J., Bae, M. A., Cheon, H. G., Shin, J. G. and Liu, K. H. (2008) In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s. Xenobiotica, 38, 1165-1176.
39. Kalgutkar, A. S., Taylor, T. J., Venkatakrishnan, K. and Isin, E. M. (2003) Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos., 31, 243-249.
40. Galetin, A., Brown, C, Hallifax, D., Ito, K. and Houston, J. B. (2004) Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Dispos., 32,1411-1420.
41. Soars, M. G., Grime, K. and Riley, R. J. (2006) Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica, 36, 287-299.
42. Emoto, C. and Iwasaki, K. (2007) Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b$ with recombinant P450 enzymes. Xenobiotica, 37, 986-999.
43. Quintieri, L., Palatini, P., Nassi, A., Ruzza, P. and Floreani, M. (2008) Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem. Pharmacol., 75, 1426-1437.
44. Carr, B., Norcross, R., Fang, Y, Lu, P., Rodrigues, A. D., Shou, M., Rushmore, T. and Booth-Genthe, C. (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab. Dispos., 34, 1703-1712.
45. Granfors, M. T., Wang, J. S., Kajosaari, L. L, Laitila, J., Neuvonen, P. J. and Backman, J. T. (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol, 98, 79-85.
46. Furster, C. and Wikvall, K. (1999) Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5j8 cholestane-3ar,7ar,12ar-triol in human liver microsomes. Biochim. Biophys. Ada, 1437,46-52.
47. Hiratsuka, M., Hinai, Y, Sasaki, T., Konno, Y, Imagawa, K., Ishikawa, M. and Mizugaki, M. (2007) Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab. Dispos., 35, 1730-1732.
48. Lee, H. K., Moon, J. K., Chang, C. H., Choi, H., Park, H. W., Park, B. S., Lee, H. S., Hwang, E. C, Lee, Y D., Liu, K. H. and Kim, J. H. (2006) Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 iso- forms. Drug Metab. Dispos., 34, 1090-1095.
49. Buratti, F. M., Leoni, C. and Testai, E. (2006) Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides. Toxicol. Lett., 167, 245-255.
50. Chang, T. K. and Yeung, R. K. (2001) Effect of frani-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin (9 dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can. J. Physiol. Pharmacol., 79, 220-226.
51. Ghosal, A., Hapangama, N., Yuan, Y, Lu, X., Home, D., Patrick, J. E. and Zbaida, S. (2003) Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes. Biopharm. Drug Dispos., 24, 375-384.
52. Lin, Y. H. and Peng, F. C. (2008) Predicting the contribution of rat cytochrome P-450 3A1, 3A2 and human cytochrome P-450 3A4, 3A5 to territrem a 4/J-C hydroxylation using the relative activity factor. J. Toxicol. Environ. Health A, 71, 1407-1414.
53. Ma, B., Polsky-Fisher, S. L., Vickers, S., Cui, D. and Rodrigues, A. D. (2007) Cytochrome P450 3 A-dependent metabolism of a potent and selective y-aminobutyric acid q;2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics. Drug Metab. Dispos., 35, 1301-1307.
54. Murayama, N., Imai, N., Nakane, T., Shimizu, M. and Yamazaki, H. (2007) Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem. Pharmacol., 73, 2020-2026.
55. Kasahara, M., Suzuki, H. and Komiya, I. (2000) Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the hu man CYP isoforms. Drug Metab. Dispos., 28,409-417.
56. Huang, Y, Okochi, H., May, B. C, Legname, G., Prusiner, S. B., Benet, L. Z., Guglielmo, B. J. and Lin, E. T. (2006) Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab. Dispos., 34, 1136-1144.
57. Lukkari, E., Taavitsainen, P., Juhakoski, A. and Pelkonen, O. (1998) Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol. ToxicoL., 82, 161-166.
58. Treluyer, J. M., Bowers, G., Cazali, N., Sonnier, M., Rey, E., Pons, G. and Cresteil, T. (2003) Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab. Dispos., 31, 275-281.
59. Desta, Z., Ward, B. A., Soukhova, N. V. and Flockhart, D. A. (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther., 310, 1062-1075.
60. Ghosal, A., Chowdhury, S. K., Tong, W., Hapangama, N., Yuan, Y, Su, A. D. and Zbaida, S. (2006) Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab. Dispos., 34, 628-635.
61. Jaakkola, T., Laitila, J., Neuvonen, P. J. and Backman, J. T. (2006) Pioglitazone is metabolized by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin. Pharmacol. ToxicoL., 99, 44-51.
62. Jacobsen, W., Kirchner, G., Hallensleben, K., Mancinelli, L., Deters, M., Hackbarth, L, Benet, L. Z., Sewing, K. F. and Christians, U. (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3 hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Dispos., 27, 173-179.
63. Madan, A., Fisher, A., Jin, L., Chapman, D. and Bozigian, H. P. (2007) In vitro metabolism of indiplon and an assessment of its drug interaction potential. Xenobiotica, 37, 736-752.
64. Pearce, R. E., Gotschall, R. R., Kearns, G. L. and Leeder, J. S. (2001) Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab. Dispos., 29, 1548-1554.
65. Zhu, M., Zhao, W., Jimenez, H., Zhang, D., Yeola, S., Dai, R., Vachharajani, N. andMitroka, J. (2005) Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos., 33, 500-507.
66. Bakken, G. V., Rudberg, L, Christensen, H., Molden, E., Refsum, H. and Hermann, M. (2009) Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome £5. Drug Metab. Dispos., 37, 254-258.
67. Yasui-Furukori, N., Hidestrand, M., Spina, E., Facciola, G., Scordo, M. G. and Tybring, G. (2001) Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos., 29, 1263-1268.
68. Prueksaritanont, T., Ma, B. and Yu, N. (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br. J. Clin. Pharmacol., 56, 120-124.
69. Miller, K. K., Cai, J., Ripp, S. L., Pierce, W. M. Jr., Rushmore, T. H. and Prough, R. A. (2004) Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab. Dispos., 32, 305-313.
70. Sharma, S., Ou, J., Strom, S., Mattison, D., Caritis, S. and Venkataramanan, R. (2008) Identification of enzymes involved in the metabolism of 17ar-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth. Drug Metab. Dispos., 36, 1896-1902.
71. Miyazawa, M., Shindo, M. and Shimada, T. (2001) Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes. Drug Metab. Dispos., 29, 200-205.
72. Pike, M. G., Mays, D. C, Macomber, D. W. and Lipsky, J. J. (2001) Metabolism of a disulfiram metabolite, S -methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab. Dispos., 29, 127-132.
73. Xu, Y, Hashizume, T., Shuhart, M. C, Davis, C. L., Nelson, W. L., Sakaki, T., Kalhorn, T. E, Watkins, P. B., Schuetz, E. G. andThummel, K. E. (2006) Intestinal and hepatic CYP3A4 catalyze hy- droxylation of la,25-dihydroxyvitamin D3: implications for drug-induced osteomalacia. Mol. Pharmacol., 69, 56-65.
74. Gibbs, M. A., Thummel, K. E., Shen, D. D. and Kunze, K. L. (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos., 27, 180-187.
75. Isoherranen, N., Ludington, S. R., Givens, R. C, Lamba, J. K., Pusek, S. N., Dees, E. C, Blough, D. K., Iwanaga, K., Hawke, R. L., Schuetz, E. G., Watkins, P. B., Thummel, K. E. and Paine, M. F. (2008) The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab. Dispos., 36, 146-154.
76. Zhou, S., Chan, E., Lim, L. Y., Boelsterli, U. A., Li S. C, Wang, J., Zhang, Q., Huang, M. and Xu, A. (2004) Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 5, 415-442.
77. Ernest, C. S., 2nd, Hall, S. D. and Jones, D. R. (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther., 312, 583-591.
78. Pearson, J. T., Wahlstrom, J. L., Dickmann, L. J., Kumar, S., Halpert, J. R., Wienkers, L. C, Foti, R. S. and Rock, D. A. (2007) Differential time-dependent inactivation of P450 3 A4 and P450 3 A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem. Res. Toxicol., 20, 1778-1786.
79. Zhao, X. J., Jones, D. R., Wang, Y. H., Grimm, S. W and Hall, S. D. (2002) Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica, 32, 863-878.
80. Wang, Y. H., Jones, D. R. and Hall, S. D. (2005) Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab. Dispos., 33, 664-671.
81. Fukuda, T, Onishi, S., Fukuen, S., Ikenaga, Y, Ohno, M., Hoshino, K., Matsumoto, K., Maihara, A., Momiyama, K., Ito, T, Fujio, Y and Azuma, J. (2004) CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J., 4, 34-39.
82. Dennison, J. B., Jones, D. R., Renbarger, J. L. and Hall, S. D. (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther., 321, 553-563.
83. Dennison, J. B., Mohutsky, M. A., Barbuch, R. J., Wrighton, S. A. and Hall, S. D. (2008) Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J. Pharmacol. Exp. Ther., 327, 248-257.
84. Niwa, T., Shiraga, T. and Takagi, A. (2005) Drug-drug interaction of antifungal drugs. Yakugaku Zasshi, 125, 795-805 (in Japanese).
85. Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L. Jr., Bhat, K., Kim, R. B. and Wilkinson, G. R. (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics, 13, 595-606.
86. Yu, K. S., Cho, J. Y, Jang, I. J., Hong, K. S., Chung, J. Y, Kim, J. R., Lim, H. S., Oh, D. S., Yi, S. Y, Liu, K. H., Shin, J. G. and Shin, S. G. (2004) Effect of the CYP3A5 genotype on the pharma- cokinetics of intravenous midazolam during inhib ited and induced metabolic states. Clin. Pharmacol. Ther., 76, 104-112.
87. He, P., Court, M. H., Greenblatt, D. J. and Von Moltke, L. L. (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther., 11, 373-387.
88. Bakken, G. V, Rudberg, L, Christensen, H., Molden, E., Refsum, H. and Hermann, M. (2007) Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin. Pharmacol. Ther., 82, 410-426.
89. Mouly, S. J., Matheny, C, Paine, M. F, Smith, G., Lamba, J., Lamba, V, Pusek, S. N., Schuetz, E. G., Stewart, P. W and Watkins, P. B. (2005) Variation in oral clearance of saquinavir is predicted by CYP3 A5* 1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther., 78, 605-618.